(Neuro-)Endokrine Tumoren des Magens sind auf dem Vormarsch: Gute Prognose bei frühem Nachweis

Scherübl, Hans; Faiss, Siegbert; Hu, Jahn; Rm, Liehr; Schwertner, C.; Steinberg, J.; Stölzel, Ulrich; Weinke, Thomas; Zimmer, Thomas; Klöppel, Günter

doi:10.1055/s-0029-1233975

Cited by 5 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most duodenal NETs are discovered at an early treatable stage (tumor diameter ≤10 mm) [69,70]. In the instances when tumors are associated with a syndrome, for example ZES, lesions are often metastatic [71].…”

Section: Duodenal Gep-nets-g-and D-cell Tumorsmentioning

confidence: 99%

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

Schimmack

Svejda

Lawrence

et al. 2011

Langenbecks Arch Surg

143

130

View full text Add to dashboard Cite

The gastrointestinal tract and pancreas exhibit ~17 different neuroendocrine cell types, but neither the cell of origin nor the biological basis of GEP-NETs is understood. This review examines GEP-NETs from the cellular and molecular perspective and addresses the distinct patterns of functional tumor biology pertinent to clinicians. Although grouped as a neoplastic entity (NETs), each lesion is derived from distinct cell precursors, produces specific bioactive products, exhibits distinct chromosomal abnormalities and somatic mutation events and has uniquely dissimilar clinical presentations. GEP-NETs demonstrate very different survival rates reflecting the intrinsic differences in malignant potential and variations in proliferative regulation. Apart from the identification of the inhibitory role of the somatostatin receptors, there is limited biological knowledge of the key regulators of proliferation and hence a paucity of successful targeted therapeutic agents. IGF-I, TGFβ and a variety of tyrosine kinases have been postulated as key regulatory elements; rigorous data is still required to define predictably effective and rational therapeutic strategy in an individual tumor. A critical issue in the clinical management of GEP-NETs is the need to appreciate both the neuroendocrine commonalities of the disease as well as the unique characteristics of each tumor. The further acquisition of a detailed biological and molecular appreciation of GEP-NETs is vital to the development of effective management strategy.

show abstract

Section: Duodenal Gep-nets-g-and D-cell Tumorsmentioning

confidence: 99%

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

Schimmack

Svejda

Lawrence

et al. 2011

Langenbecks Arch Surg

143

130

View full text Add to dashboard Cite

show abstract

Chirurgische Therapie gastroduodenaler neuroendokriner Neoplasien

Fendrich

Bartsch

2016

Chirurg

View full text Add to dashboard Cite

Gastroduodenal neuroendocrine tumors are rare but an increase in incidence has been recognized worldwide over the past 35 years. At the same time the prognosis of patients has substantially improved because the majority of these tumors can now be detected at an early stage. Neuroendocrine neoplasms (NENs) of the stomach are the most frequent neoplasms of neuroendocrine origin in the gastrointestinal tract. The therapeutic management of these tumors is complicated by the fact that they must be classified not only by staging and grading but also according to their pathophysiological background (types). These types differ in biological behavior and therefore have an influence on the therapeutic concept. Because more than 90 % of duodenal NENs are often asymptomatic and are as a rule identified at a curable stage, resection of the tumor should always be the first line of therapy. The therapeutic strategies vary from local endoscopic resection (duodenotomy with excision) up to pancreas retaining duodenectomy and pylorus retaining or classical Whipple procedures. This article presents the various surgical approaches to gastric and duodenal NENs.

show abstract

Chirurgie neuroendokriner Tumoren des gastroenteropankreatischen Systems (GEP-NET)

et al. 2012

View full text Add to dashboard Cite

Surgical treatment is still the only curative treatment proven for patients with neuroendocrine tumors (NET) of the gastroenteropancreatic system. In addition to the therapy of incidental findings, the treatment of NET with variable aggressiveness and often good long-term prognosis requires a thorough preoperative assessment and a surgical procedure that is based on each individual case. Treatment can be surgery alone (if the disease is locally confined) or can be combined with other therapies. Early NET of the stomach and rectum can be cured endoscopically without further diagnostics, while early findings of the appendix can be treated by an appendectomy. Functionally active pancreatic NET and NET of the small intestine are often preoperatively diagnosed based on symptoms. Thus, it is possible to refer the patient to a NET center, if necessary. Stratification of the necessary treatment combination can be made early. An alternative to radical surgical treatment is the operative reduction of the tumor size and hormone production in metastasized NET, which can lead to improved life expectancy and quality of life. Combination with other treatment forms is absolutely necessary in these patients. It has been proven useful to divide the large group of NET based on the different tumor locations, hormone activity, and the degree of differentiation of the tumor. Early forms, locoregionally limited tumor stages, and tumor stages with distant metastases are considered separately.

show abstract

(Neuro-)Endokrine Tumoren des Magens sind auf dem Vormarsch: Gute Prognose bei frühem Nachweis

Cited by 5 publications

References 28 publications

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

Chirurgische Therapie gastroduodenaler neuroendokriner Neoplasien

Chirurgie neuroendokriner Tumoren des gastroenteropankreatischen Systems (GEP-NET)

Contact Info

Product

Resources

About